sponsored
PatientsVille.com Logo

PatientsVille

Jonas Medical Research Studies

Up-to-date List of Jonas Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Jonas Medical Research Studies

Rank Status Study
1 Recruiting Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
Condition: Pediatric Acute Myeloblastic Leukemia
Interventions: Drug: Randomisation course 1 mitoxantrone versus DaunoXome;   Drug: Randomisation course 2 ADxE versus FLADx
Outcome Measures: Minimal residual disease;   Event-free survival;   Acute toxicity;   Long-term toxicity;   Overall survival
2 Recruiting Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery
Conditions: Diabetes;   Peripheral Arterial Disease;   Arterial Occlusive Disease
Interventions: Procedure: Hyperbaric Oxygen treatment (HBO);   Procedure: Sham HBO
Outcome Measures: Time to complete healing of operative wounds;   Number of wound infections at 7 days assessed by ASEPSIS score. A score over 20 will be considered as a wound infection.;   Number of wound infections at 30 days assessed by ASEPSIS score. A score over 20 will be considered as a wound infection.;   The severity of wound infection defined as by ASEPSIS score: 0-10= satisfactory healing 11-20= disturbed healing 21-30= minor wound infection 31-40= moderate wound infection >40= severe wound infection.;   A combination of any wound infection and/or unhealed wounds at 30 days (combined endpoint).;   SF-36 score;   Major amputation or death. This will be assessed as "amputation-free survival". A major amputation is defined as any ipsilateral amputation through or above the ankle.;   Tissue perfusion and oxygenation on dorsum of foot on operated extremity as assessed by Transcutaneous oximetry during normobaric air breathing and after 6 min normobaric 100% oxygen challenge;   HBO complications (confinement anxiety, barotrauma, oxygen convulsions)
3 Recruiting Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
Conditions: Lung Transplantation;   Chronic Obstructive Pulmonary Disease
Intervention:
Outcome Measures: morphometry;   adverse events
4 Recruiting Knee Arthroscopy Cohort Southern Denmark (KACS)
Conditions: Meniscus Injury;   Knee Osteoarthritis
Intervention: Procedure: Arthroscopic Meniscus Surgery
Outcome Measures: Knee Injury and Osteoarthritis Outcome Score (KOOS);   Medical Outcomes Study 36-Item Short Form Health Survey (SF-36);   Patient Acceptable Symptom State (PASS);   Treatment failure (TF)
5 Recruiting Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial
Condition: Hypoxaemia
Intervention:
Outcome Measure: Time to correction of SpO2
6 Unknown  Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia
Conditions: Critical Limb Ischemia;   Arterial Occlusive Disease;   Pain;   Ischemia
Interventions: Drug: pregabalin;   Drug: placebo
Outcome Measures: Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.;   Improvement in the Short Form 36 (SF-36) parameter "bodily pain".;   The amount, dose and duration of concomitant pain medication use during study compared to use before study.;   Safety outcomes and adverse events will be examined and recorded throughout the study. Patient reported dizziness will be recorded separately in the CRF, as well as blood pressure at visits.
7 Recruiting Karolinska Cardiorenal Theme-centre and StockholmHeartbank
Conditions: Chronic Kidney Disease;   Chronic Renal Failure;   Acute Coronary Syndrome;   Ischemic Heart Disease;   Myocardial Infarction
Intervention:
Outcome Measures: Composite;   Renal function decline;   Vascular function
8 Recruiting Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain
Condition: Non-specific Chronic Back Pain
Intervention: Behavioral: Eye-Movement-Desensitization-Reprocessing
Outcome Measure: Change in pain intensity
9 Recruiting Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cediranib maleate;   Drug: lenalidomide;   Other: laboratory biomarker analysis
Outcome Measures: Maximum-tolerated dose defined as the highest dose level such that < 2 of 6 patients experience dose-limiting toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);   Progression-free survival (PFS) (Phase II);   Objective response rate (Phase I);   Overall survival (OS);   Percent change in tumor size (Phase II);   Adverse events as assessed by NCI CTCAE version 4.0;   Serial measurements of TSH and thyroglobulin;   Presence or absence of B-RAF and RAS mutations
10 Recruiting Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients
Condition: Colitis, Ulcerative
Interventions: Drug: SB012;   Drug: Placebo
Outcome Measures: Efficacy: Total Mayo score (4 weeks comparison);   Efficacy: Total Mayo score (8 weeks comparison);   Efficacy: Endoscopic Mayo score (4 and 8 weeks comparison);   Efficacy/Pharmacodynamics: Glucocorticoid consumption;   Safety: Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
11 Recruiting Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Condition: Mild to Moderate Atopic Dermatitis
Interventions: Drug: SB011, 2 % (Water/Oil/Water) emulsion of hgd40;   Drug: Multiple W/O/W formulation, active ingredient-free vehicle
Outcome Measures: Change of local SCORing atopic dermatitis (SCORAD) from baseline to Day 15.;   The change from baseline in modified local SCORAD;   Modified local SCORAD;   Change from baseline in transepidermal water loss (TEWL);   TEWL on Days 1, 3, 5, 8, 12, and 15;   Subjective assessment of pruritus using a 10-point rating scale;   Subjective efficacy assessment on Days 3, 5, 8, 12 and 15;   Subjective dermal tolerability assessment using a 5-point rating scale on Days 3, 5, 8, 12 and 15;   Pharmacokinetic outcome measure;   Physical examination of the skin and Vital signs;   Adverse Events;   Standard Safety laboratory
12 Recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
Outcome Measures: Identification of molecular biomarkers;   Safety of metastatic biopsies during bevacizumab therapy
13 Unknown  Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema
Conditions: Diabetic Retinopathy;   Diabetic Macular Edema
Intervention: Drug: Intravitreal injection (triamcinolone acetonide)
Outcome Measures: Visual acuity, no of treatments, duration of efficacy;   intraocular pressure, retinal thickness
14 Not yet recruiting A Randomized Controlled Trial of a Video Decision Aid in the ICU
Condition: Admission to the ICU With Life-threatening Advanced Illness Including Advanced Heart Disease, Kidney Disease, Lung Disease, Gastrointestinal Disease and Cancer.
Intervention: Behavioral: video decision aid
Outcome Measures: preference for goal of care regarding medical interventions (e.g., CPR, intubation, etc.);   level of medical care delivered to patient at time of death or discharge from the ICU;   anxiety and depression;   satisfaction with ICU experience;   number of medical interventions during ICU stay
15 Recruiting Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
Outcome Measures: Objective response rate, defined as the proportion of patients who have had a PR or CR as assessed by the RECIST v1.1;   Duration of objective response as assessed by the RECIST v1.1;   Progression-free survival;   Overall survival;   Incidence of severe (grade 3+) adverse events, graded according to the National Cancer Institute CTCAE v4.0;   Percent change in serum tumor marker thyroglobulin levels;   Response of cabozantinib-s-malate in bone metastasis (bone metastasis-specific progression free survival) as evaluated by functional imaging;   Bone turnover, as measured by serum and urinary markers of bone turnover;   Tumor genotype of predictive biomarker of response;   Expression levels of predictive biomarkers of response by immunohistochemistry in archived tumor tissue
16 Recruiting Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction
Conditions: Coronary Artery Disease;   Myocardial Infarction
Intervention: Procedure: Primary Percutaneous Coronary Intervention
Outcome Measures: Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance;   Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance
17 Recruiting Endomicroscopy in IBD Patients
Conditions: Crohn's Disease;   Ulcerative Colitis
Intervention:
Outcome Measure: Assessment of mucosal healing changes by confocal laser endomicroscopy
18 Recruiting A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study
Conditions: Cancer;   Cachexia
Interventions: Other: Multimodal intervention;   Other: Standard care
Outcome Measure: Feasibility of recruitment and retention
19 Recruiting Metabolic and Cardiovascular Effects of Renal Denervation
Conditions: Insulin Resistance;   Hypertension
Intervention: Procedure: Renal denervation using Medtronic Symplicity System (mono-electrode)
Outcome Measures: Adipose tissue function;   Heart rate variability;   Body composition
20 Recruiting Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated Wih High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Glucarpidase
Outcome Measures: Number of Participants with Adverse Event to HD-MTX treatment in NOPHO ALL-2008 as a measure of toxic Mtx concentrations in blood, nephrotoxicity, hepatotoxicity, mucositis, MTX elimination time and permanent kidney damage.;   Evaluate time at hospital and health costs

These studies may lead to new treatments and are adding insight into Jonas etiology and treatment.

A major focus of Jonas research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Jonas